Soluble Fas might serve as a diagnostic tool for gastric adenocarcinoma

Boroumand-Noughabi, S. and Sima, H. R. and Ghaffarzadehgan, K. and Jafarzadeh, M. and Raziee, H. R. and Hosseinnezhad, H. and Moaven, O. and Rajabi-Mashhadi, M. T. and Azarian, A. A. and Mashhadinejad, M. and Tavakkol-Afshari, J. (2010) Soluble Fas might serve as a diagnostic tool for gastric adenocarcinoma. BMC Cancer, 10.

[img] Text

Download (958kB)


Background: Fas (Apo-1/CD95) and its specific ligand (FasL) are key elements in apoptosis. They have been studied in different malignancies but there are few published studies about the soluble forms of these markers (i.e. sFas/sFasL) in gastric cancer. We have compared the serum levels of sFas/sFasL in gastric adenocarcinoma patients and cases with pre-neoplastic lesions as potential markers for early diagnosis, and investigated their relation with clinicopathological characteristics.Methods: Fifty-nine newly-diagnosed cases of gastric adenocarcinoma who had undergone gastrectomy, along with 62 endoscopically- and histologically-confirmed non-cancer individuals were enrolled in this study. sFas/sFasL serum levels were detected by Enzyme Linked Immunosurbent Assay.Results: Mean serum sFas level was significantly higher in gastric cancer patients than in control group (305.97 ± 63.71 (pg/ml) vs. 92.98 ± 4.95 (pg/ml), P < 0.001); while the mean serum level of sFasL was lower in patients with gastric adenocarcinoma (0.138 ± 0.04 (pg/ml) vs. 0.150 ± 0.02 (pg/ml), P < 0.001). Mean serum levels of sFas/sFasL were significantly different in both intestinal/diffuse and cardiac/non-cardiac subtypes when compared to the control group (P < 0.001). There was an increase in the serum level of sFas from the first steps of pre-neoplastic lesions to gastric adenocarcinoma (P < 0.001). Patients who had no lymph node involvement (N0) showed significantly higher serum levels of sFas compared to others (P = 0.044).Conclusions: Production of sFas may play a critical role in the carcinogenesis of intestinal-type gastric cancer. sFas serum level may serve as a non-invasive tool for early diagnosis of gastric cancer. © 2010 Boroumand-Noughabi et al; licensee BioMed Central Ltd.

Item Type: Article
Additional Information: Cited By :18 Export Date: 16 February 2020 CODEN: BCMAC Correspondence Address: Sima, H.R.; Department of Internal Medicine, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran; email:
Uncontrolled Keywords: Fas antigen Fas ligand opiate FAS protein, human FASLG protein, human tumor marker adult aged article blood analysis cigarette smoking controlled study diagnostic value early diagnosis educational status enzyme linked immunosorbent assay esophagogastroduodenoscopy female gastrectomy Helicobacter infection histopathology human human tissue lymph node metastasis major clinical study male non invasive measurement opiate addiction precancer social status stomach adenocarcinoma stomach biopsy adenocarcinoma blood cancer staging case control study chi square distribution Iran middle aged pathology prediction and forecasting stomach tumor treatment outcome Antigens, CD95 Case-Control Studies Chi-Square Distribution Early Detection of Cancer Enzyme-Linked Immunosorbent Assay Fas Ligand Protein Humans Neoplasm Staging Predictive Value of Tests Stomach Neoplasms Tumor Markers, Biological
Subjects: WI Digestive System
Divisions: Mashhad University of Medical Sciences
Depositing User: mr lib4 lib4
Date Deposited: 03 Mar 2020 05:25
Last Modified: 03 Mar 2020 05:25

Actions (login required)

View Item View Item